Platelet Response During the Second Cycle of Decitabine Can Predict Response and Survival for Myelodysplastic Syndrome

Samsung Medical Center

Status: Unknown

Conditions: Myelodysplastic Syndrome

Study type: Observational

Funder types: Other

Identifiers

NCT02045654

2014-01-086

Details and patient eligibility

About

To assess the efficacy of decitabine and identify predictors for response to decitabine therapy.

Full description

• Histologically confirmed Myelodysplastic syndrome Diagnosed with MDS (de novo or secondary) based on the World Health Organization (WHO) classifications
• Survival and response Analysis
• Response rate
• Overall survival
• Leukemia free survival

Enrollment: 1 estimated patient

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• Histologically confirmed Myelodysplastic syndrome Diagnosed with MDS (de novo or secondary) based on the World Health Organization (WHO) classifications

Trial design

1 participants in 1 patient group

MDS patients

Description:

MDS patients who were treated with decitabine